Long-range oncogenic activation of Igh-c-myc translocations by the Igh 3′ regulatory region

Nature

Volumn 462, Issue 7274, 2009, Pages 803-807

  Gostissa, Monica ^a,b,c   Yan, Catherine T ^a,b,c   Bianco, Julia M ^a,b,c   Cogné, Michel ^d   Pinaud, Eric ^d   Alt, Frederick W ^a,b,c  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE;

CELL ORGANELLE; DEVELOPMENTAL STAGE; GENE; GENETIC ANALYSIS; TRANSLOCATION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CONTROLLED STUDY; ENHANCER REGION; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; GENE LOCUS; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC RECOMBINATION; GENETIC TRANSCRIPTION; IMMUNOGLOBULIN HEAVY CHAIN GENE; INTRON; MOUSE; NONHUMAN; ONCOGENE C MYC; PRE B LYMPHOCYTE; PRIORITY JOURNAL; STEM CELL; TRANSGENIC MOUSE; VDJ EXON;

MUS MUSCULUS;

EID: 72049100181     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08633     Document Type: Article

References (30)

1. Küppers, R. & Dalla-Favera, R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20, 5580-5594 (2001).
2. Lieber, M. R., Yu, K. & Raghavan, S. C. Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations. DNA Repair (Amst.) 5, 1234-1245 (2006).
3. Ramiro, A. et al. The role of activation-induced deaminase in antibody diversification and chromosome translocations. Adv. Immunol. 94, 75-107 (2007).
4. Robbiani, D. F. et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 135, 1028-1038 (2008).
5. Bassing, C. H., Swat, W. & Alt, F. W. The mechanism and regulation of chromosomal V(D)J recombination. Cell 109 (suppl.), S45-S55 (2002).
6. Chaudhuri, J. et al. Evolution of the immunoglobulin heavy chain class switch recombination mechanism. Adv. Immunol. 94, 157-214 (2007).
7. Henderson, A. & Calame, K. Transcriptional regulation during B cell development. Annu. Rev. Immunol. 16, 163-200 (1998).
8. Cogné, M. et al. A class switch control region at the 39 end of the immunoglobulin heavy chain locus. Cell 77, 737-747 (1994).
9. Khamlichi, A. A., Pinaud, E., Decourt, C., Chauveau, C. & Cogne, M. The 39 IgH regulatory region: a complex structure in a search for a function. Adv. Immunol. 75, 317-345 (2000).
10. Pinaud, E. et al. Localization of the 39 IgH locus elements that effect long-distance regulation of class switch recombination. Immunity 15, 187-199 (2001).
11. Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533-538 (1985).
12. Janz, S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst.) 5, 1213-1224 (2006).
13. Schmidt, E. V., Pattengale, P. K., Weir, L. & Leder, P. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model. Proc. Natl Acad. Sci. USA 85, 6047-6051 (1988).
14. Truffinet, V. et al. The 39IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype. J. Immunol. 179, 6033-6042 (2007).
15. Wang, J. & Boxer, L. M. Regulatory elements in the immunoglobulin heavy chain gene 39-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells. J. Biol. Chem. 280, 12766-12773 (2005).
16. Yan, Y., Park, S. S., Janz, S. & Eckhardt, L. A. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 39 regulatory region induces MYC expression at the immature stage of B cell development. Genes Chromosom. Cancer 46, 950-959 (2007).
17. Manis, J. P., Tian, M. & Alt, F. W. Mechanism and control of class-switch recombination. Trends Immunol. 23, 31-39 (2002).
18. Madisen, L. & Groudine, M. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Genes Dev. 8, 2212-2226 (1994).
19. Dariavach, P., Williams, G. T., Campbell, K., Pettersson, S. & Neuberger, M. S. The mouse IgH 39-enhancer. Eur. J. Immunol. 21, 1499-1504 (1991).
20. Lieberson, R., Giannini, S. L., Birshtein, B. K. & Eckhardt, L. A. An enhancer at the 39 end of the mouse immunoglobulin heavy chain locus. Nucleic Acids Res. 19, 933-937 (1991).
21. Lieber, M. R. The mechanism of human nonhomologous DNA end joining. J. Biol. Chem. 283, 1-5 (2008).
22. Zhu, C. et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109, 811-821 (2002).
23. Difilippantonio, M. J. et al. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J. Exp. Med. 196, 469-480 (2002).
24. Yan, C. T. et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 449, 478-482 (2007).
25. Wang, J. H. et al. Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J. Exp. Med. 205, 3079-3090 (2008).
26. Wang, J. H. et al. Mechanisms promoting translocations in editing and switching peripheral B cells. Nature 460, 231-236 (2009).
27. Franco, S. et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol. Cell 21, 201-214 (2006).
28. Ramiro, A. R. et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 440, 105-109 (2006).
29. Neri, A., Barriga, F., Knowles, D. M., Magrath, I. T. & Dalla-Favera, R. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc. Natl Acad. Sci. USA 85, 2748-2752 (1988).
30. Frank, K. M. et al. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol. Cell 5, 993-1002 (2000).